Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Nicole Perera-Low"'
Autor:
R. Shi, Frances A. Shepherd, P. Rogalla, M. Tsao, Aline Fusco Fares, A. Grindley, Michael Cabanero, Kazuhiro Yasufuku, P. A. Bradbury, L. Nguyen, Adrian G. Sacher, Erin L. Stewart, Natasha B. Leighl, Frances Allison, G. Liu, N. Pham, Nicole Perera-Low, Prodipto Pal, Devalben Patel, Sebastiao N. Martins-Filho
Publikováno v:
Journal of Thoracic Oncology. 14:S323-S324
Autor:
Mike Sung, Nazanin Nouriany, Nicole Perera-Low, M. Sawczak, Andrea Foster, Ronald Feld, Geoffrey Liu, Dianne Zawisza, Tuhina Paul, Frances A. Shepherd, Charles Henry Lim, Natasha B. Leighl
Publikováno v:
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 11(1)
ObjectivesClinical trials of therapies for non–small cell lung cancer (NSCLC) are increasingly requiring mandatory tumor samples or research biopsies, both of which are potential barriers to trial participation. We assessed the impact of performanc
Autor:
Natasha B. Leighl, L. Wong, Nicole Perera-Low, M. Iqbal, D. Laurence, M. Sawczak, Parneet Cheema, Ronald Burkes, I. Carvalhana, M. Tsao, L. Markin, S. Owen, Janessa Laskin, G. Liu, J. Rothenstein, Tristan A. Barnes
Publikováno v:
Journal of Thoracic Oncology. 12:S2225
Autor:
Leslie Markin, Tristan A. Barnes, Geoffrey Liu, Linda Wong, David Laurence, Ilda Carvalhana, Natasha B. Leighl, Ronald Burkes, S. Owen, Ming-Sound Tsao, Mussawar Iqbal, Jeffrey Rothenstein, Janessa Laskin, M. Sawczak, Nicole Perera-Low, Parneet K. Cheema
Publikováno v:
Journal of Clinical Oncology. 35:e18329-e18329
e18329 Background: Detection of EGFRmutations in circulating tumor DNA (ctDNA) in peripheral blood has been shown to have high concordance with definitive tumor biopsy samples. Patients’ perceived value and willingness to pay for novel technology c
Autor:
Natasha B. Leighl, Frances A. Shepherd, Geoffrey Liu, Ronald Feld, M. Sawczak, Nicole Perera-Low, Tuhina Paul, Nazanin Ziapour Nouriany, Mike Sung, Charles Henry Lim
Publikováno v:
Journal of Clinical Oncology. 33:6534-6534
6534 Background: The evolution of targeted therapy in NSCLC has led to growing complexity of clinical research and a heightened expectation of clinical benefit for participants. Clinical trials in ...